Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

100.0%

4 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07159828Phase 1Terminated

A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors

Role: collaborator

NCT05397093Phase 1Terminated

ITIL-306 in Advanced Solid Tumors

Role: lead

NCT05050006Phase 2Terminated

ITIL-168 in Advanced Melanoma

Role: lead

NCT05393635Phase 1Withdrawn

ITIL-168 in Advanced Solid Tumors

Role: lead

All 4 trials loaded